PhD, State University of New York at Buffalo (2004)
BS, University of Jordan
Employment:
UB-IRB Committee member, University at Buffalo (2018-present)
Research Director, Medicine, Division of Endocrinology, Diabetes and Metabolism (2005-present)
Research Associate Professor, Endocrinology, State University of New York at Buffalo Jacobs School of Medicine & Biomedical Sciences (2014-present)
Awards and Honors:
Internal Medicine Training Program Teaching appreciation award (2013)
The Pharmacia Corporation International Award for Excellence in Published Clinical Research (2001)
Grants and Sponsored Research:
January 2019–December 2024 Triple therapy for T1DM with insulin, semaglutide and dapagliflozin JDRF Role: Co-Principal Investigator $1,641,000
January 2018–December 2024 An Investigation into the effects of Dapagliflozin on Ketogensis in Type 1 Diabetes AstraZeneca Pharmaceuticals LP Role: Co-Investigator $735,000
September 2022–June 2024 3- Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes treated with Multiple Daily Injection Therapy Lilly Role: Co-Investigator $258,000
December 2023–May 2024 3- A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP) GSK Role: Contributor $25,200
September 2022–April 2024 2- A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabetes on Multiple Display Injections Lilly Role: Co-Investigator $283,500
December 2021–December 2022 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment CTSI Role: Principal Investigator $50,000
July 2021–July 2022 LIGHT-UP Study service contract Gelesis Inc Role: Contributor $371,000
December 2012–November 2019 Effects of liraglutide treatment in overweight or obese patients with type 1 diabetes JDRF Role: Co-Investigator $600,000
August 2012–July 2017 Liraglutide as an Additional treatment in Type 1 diabetes NIH/NIDDK Role: Co-Investigator $1,580,000
May 2024 1- A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes, Moderate or Severe Renal Impairment with Inadequate Glycemic Control on Basal Insulin with or without Metformin and/or SGLT2 inhibitor (TRANSCEND-T2D-3) Lilly Role: Co-Investigator $315,000
May 2024 1- Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism AbbVie Role: Co-Investigator $340,200
January 2023 3- NATiV3: A randomized, double blind, placebo-controled, multicentre, Phase 3 study evaluating long term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis. Inventiva Role: Contributor $245,700
Ghanim H, Thethi TK, Abuaysheh S, Fonseca V, Dandona P. (2023) Vasoactive mediators of hypertension in obesity. American journal of physiology. Endocrinology and metabolism (Oct), 325(4): E406-E411. doi:10.1152/ajpendo.00209.2022
Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S, Dandona P. (2012) Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab (Sep), 97(9): 3333-3341.
Awards of Excellence for Promoting Inclusion and Cultural Diversity.; Reviewer (2024)
Medical Students Annual Reseach Forum. Review, judge and rank posters of medical students; Reviewer and Judge (2024)
Peace Center of WNY; Volunteer (2023–present)
FY24 Training Awards Review, JDRF; Reviewer (2023)
Review, interview and rank applicants for fellowship position every year; reviewer (2023)
Reivew applicant's CV's and patriciate in interviews and ranking; Chief of Nephrology search committee (2023–2024)
JDRF FY22 Beta Improving Lives Training AWARD; REVIEWER (2021)
Reviewer for Journal of Cellular and Molecular Medicine; Reviewer (2021–present)
CTSI Translational Pilot Studies Program; Reviewer (2020)
Reviewer for Diabetes, Obesity and Metabolism; Reviewer (2020–present)
Discussion group to improve IRB function. Chair: Dr Sanjay Sethi; IRB working group (2019)
DOM Research Day abstract reviewer and poster Judge. Research performed by residents, fellows and junior faculty; Abstract Reviewer (2019–present)
Reviewer for The Journal of Clinical Endocrinology & Metabolism; Reviewer (2019–present)
Islamic Society of Niagara Frontier Sunday School Board president; Sunday School Board president (2018–present)
I have been a member of the review committee in UBIRB since 2018. Received excellent evaluation for my role and re-appointed for 3 more years till 2027; IRB review board member (2018–present)
Research Staff and volunteer's supervisor. Signing time sheets, assign duties and allocating effort; Research Staff and volunteer's supervisor (2006–present)
Member of Network of Religious Communities. Supporting peace and understanding in the WNY area; Community Representative
Provide general and specific research guidance for resident and fellows in the department and division; Endocrine Division Research Director